First robotic-guided lung ablation cases commence as part of Intuitive collaboration agreement



Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that the first robotic-guided microwave ablation of cancerous lung tissue cases have commenced at a leading UK hospital (the “Hospital”).

As announced in July 2024, the Company amended its multi-year collaboration with Intuitive and this latest robotic-guided microwave ablation procedure for lung cancer is the first clinical case using Intuitive’s Ion Endoluminal System and Creo’s MicroBlate™ Flex ablation device to take place under the amended terms of the agreement at the Hospital. The Hospital is now the second site to have performed microwave ablation procedures for lung cancer. The first UK site to perform such procedures was the Royal Brompton Hospital as part of an ongoing clinical study1 conducted by Professor Shah.

The Pioneer Programme will continue to roll-out throughout 2025 to support the collection of clinical evidence ahead of the sites entering a commercial phase, and the Company expects the number of procedures performed to grow in the current year.

Craig Gulliford, Chief Executive Officer of Creo Medical, said:

"We are delighted that this first clinical site under the Pioneer Programme, representing a second UK clinical site, has started clinical practice and successfully completed their first robotic-guided lung cancer ablation procedure using Creo’s MicroBlate Flex alongside Intuitive’s Ion Endoluminal System. With both the clinical study at the Royal Brompton and this site as part of the clinical Pioneer Programme, we now have two UK hospitals undertaking these procedures. These sites, under the amended collaboration agreement with Intuitive, will provide us with the clinical evidence needed to support the wider commercialisation of the MicroBlate Flex device. We look forward to updating shareholders on our progress.”

Further news

07 May 2026

First breakthrough case delivering targeted therapy for pancreatic lesions

Read

05 May 2026

SpydrBlade Flex used in novel bariatric endoscopic technique by leading US innovator

Read

29 April 2026

First UK private hospital use Speedboat for colorectal cancer case

Read

16 January 2026

New partnership brings Creo’s CROMA-powered GI devices to Scandinavia

Read

04 August 2025

South Wales Patient Interview Liz Thomas

Read

11 June 2025

MicroBlate™ Flex Achieves First-Patient Milestone in New European Lung Tumour Clinical Study

Read

11 June 2025

Creo Medical Secures FDA Clearance for SpydrBlade™ Flex, Advancing U.S. Market Launch

Read

28 May 2025

US Reimbursement milestone for Speedboat procedure further driving the roll-out of Creo’s products

Read

04 April 2025

Shining a Light on Gastrointestinal Endoscopy Experts

Read

20 March 2025

UK & EU Commercial launch of SpydrBlade™ Flex

Read